Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals Medical Dialogues Bureau3 Sep 2019 4:00 AM GMTNovartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of...
Novartis Rydapt wins EU approval for AML, other diseases Ruby Khatun Khatun22 Sep 2017 4:27 AM GMTZURICH: Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML)...